On Wednesday, Goldman Sachs updated its outlook on shares of Intra-Cellular Therapies (NASDAQ:ITCI), raising the price target to $79 from $74 while maintaining a Neutral rating. The company's third-quarter 2024 revenues were reported at $175.4 million, slightly surpassing the FactSet consensus of $172.3 million and aligning with Goldman Sachs' estimate of $175.2 million. Intra-Cellular also adjusted its full-year revenue guidance for 2024, now expecting between $665 million and $685 million, compared to the previous range of $650 million to $680 million.
The pharmaceutical company has expanded its sales force by an additional 150 representatives in the third quarter of 2024, as planned, to enhance its reach among primary care physicians. This expansion is part of the company's strategy to capitalize on the bipolar depression (BPD) market. Intra-Cellular also introduced a forecast for Caplyta, its flagship product, projecting over $5 billion in sales over the next decade. This estimate assumes a leading market share in BPD and major depressive disorder (MDD), along with expected net price improvements.
Goldman Sachs anticipates Intra-Cellular to become profitable by 2026 at the earliest, considering the consistent revenue growth against the expenses related to the commercial expansion for the upcoming MDD launch. The company's supplemental New Drug Application (sNDA) for MDD is expected to be filed by the end of 2024. The updated projection for peak sales of Caplyta within MDD is now $1.6 billion, an increase from the previous estimate of $1.3 billion.
Intra-Cellular shares saw a significant rise, trading up 12% on Wednesday, in contrast to the broader biotech index (XBI), which remained unchanged. This surge in stock value is largely attributed to the company's optimistic sales projection for Caplyta. The revised 12-month price target of $79 by Goldman Sachs reflects the balance between higher anticipated operating expenses in the near term and the increased peak sales forecast for Caplyta.
InvestingPro Insights
Intra-Cellular Therapies' recent performance and future outlook are further illuminated by real-time data from InvestingPro. The company's market capitalization stands at $9.08 billion, reflecting investor confidence in its growth potential. This confidence is underscored by the company's impressive revenue growth, with a 54.31% increase over the last twelve months as of Q2 2024, reaching $564.53 million. The quarterly revenue growth of 45.67% in Q2 2024 aligns with the company's strong performance mentioned in the article.
InvestingPro Tips highlight that ITCI is trading near its 52-week high, with a price that is 97.13% of its 52-week peak. This corresponds with the 12% stock price increase mentioned in the article. Additionally, the company has shown a high return over the last year, with a one-year price total return of 65.52%, indicating strong market performance.
It's worth noting that while the company is experiencing robust revenue growth, it is not yet profitable, as indicated by both the article and the InvestingPro Tip stating that analysts do not anticipate profitability this year. This aligns with Goldman Sachs' projection of profitability by 2026 at the earliest.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for ITCI, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.